Spinogenix Reports Positive Data on Alzheimer's Patients Who Continued Treatment With Tazbentetol For Up To 84 Weeks

Data ReadoutpositiveTazbentetolPositive

AI Analysis

Summary

Spinogenix reported positive data on Tazbentetol, a first-in-class oral synaptic regenerative therapy, demonstrating favorable safety and durable benefits in Alzheimer's patients treated for up to 84 weeks. Clinical case study presented at AAIC highlighted rapid cognitive improvement reported by caregivers.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Favorable safety profile and durable therapeutic benefits demonstrated in patients treated for up to 84 weeks; clinical case study presented at AAIC showed caregiver report of rapid cognitive improvement with supporting clinical outcomes

Importance:6/10

Sentiment:

0.70

Alzheimer's DiseaseClinical DataFirst-in-ClassOral TherapySynaptic RegenerationAAIC Conference

Related Companies

$TRAX $RTSL

Read the original article

Published by PR Newswire Pharma on July 14, 2026 5:56 PM

Read Original